

## 10-4155-F: Monoclonal Antibody to CD20 (Clone: B9E9) FITC Conjugated

<b>Clonality :</b>	Monoclonal
<b>Clone Name :</b>	B9E9
<b>Application :</b>	FACS
<b>Reactivity :</b>	Human
<b>Conjugate :</b>	FITC
<b>Gene :</b>	MS4A1
<b>Gene ID :</b>	931
<b>Uniprot ID :</b>	P11836
<b>Format :</b>	Purified
<b>Alternative Name :</b>	B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, CD_antigen: CD20
<b>Isotype :</b>	Mouse IgG2a, Kappa
<b>Immunogen Information :</b>	Lymphoblastoid cell line Daudi was used as the immunogen for this antibody.

### Description

CD20 is clinically validated as an immunotherapy target for B-cell lymphomas and autoimmune diseases. CD20 consists of large, intracellular, amino- and carboxyterminal portions connected by 4 membrane-spanning domains. Its high expression on malignant B cells and its reported lack of shedding from the surface make CD20 an ideal target for antibody-mediated killing. Anti-CD20 antibodies are believed to mediate the therapeutic effect by activation of complement-dependent cytotoxicity (CDC) and largely by antibody-dependent cellular cytotoxicity exerted by recruitment of innate immune effector cells expressing the Fcγ receptor IIIa.

### Product Info

<b>Amount :</b>	25 µg / 100 µg
<b>Purification :</b>	Protein G Chromatography
<b>Content :</b>	0.2 mg/ ml of Tris buffer containing 0.05% sodium azide.
<b>Storage condition :</b>	Store the antibody at 4°C, stable for 6 months.

### Application Note

FACS: 0.5-1 µg/10<sup>6</sup> cells




Fig-1: Cell surface flow analysis of FITC conjugated hCD20 on PBMC cells using 0.5 µg/ 10<sup>6</sup> cells. Green represents isotype control (ABEOMICS); red represents FITC conjugated anti-CD20 antibody (10-4155-F).